Peptide Library

Human study PLS-00046

The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.

Prospective cohort · 94 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.primary · Blood purification · 2024-08-07 · PMID 39111290 · DOI

Design and participants

Design
Prospective cohort
Population
Prevalent chronic hemodialysis patients with end-stage kidney disease. A control group was used for comparison of MOTS-c levels.
Conditions
End-stage kidney disease, Chronic hemodialysis, Cardiovascular disease risk
Setting
Multicenter, prospective observational study in hemodialysis units
Planned enrollment (registry)
Not reported
Enrolled
94
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no MOTS-c was administered.

    The authors concluded (paraphrased): In hemodialysis patients, circulating MOTS-c may add information that refines cardiovascular and mortality risk prediction beyond cohort-related risk factors. Larger and more heterogeneous cohorts are needed to generalize the findings.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: MOTS-c was measured as an endogenous circulating biomarker, not administered, so no treatment effect can be inferred.
    • small or imprecise: Only 94 hemodialysis patients were studied, and confidence intervals reach the null (HR 95% CI 1.000-1.025).
    • abstract only: Only the PubMed abstract is available; methods, funding and conflicts are not reported in the record.
    • other: MOTS-c was measured as an endogenous biomarker. No one received the compound, so the study gives no evidence on its administration, efficacy or safety.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 39111290, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 39111290, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 39111290, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 39111290, abstract (Introduction, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).